To reformulate metered-dose inhaler
Cambridge company Mundipharma and Wiltshire-based Vectura, owned by Philip Morris International, have announced plans to reformulate the flutiform pressurised metered-dose inhaler as a commitment to reducing the product’s carbon footprint.
Mundipharma and Vectura will now progress development of the reformulation of flutiform following long-term collaboration, planning and lab-scale development work.
The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
https://www.vectura.com/about/news/mundipharma-and-vectura-announce-plans-to-reformulate-flutiform/